RAPT Stock Based Compensation from 2010 to 2024

RAPT Stock

USD 1.23 0.11 9.82%

RAPT Therapeutics Stock Based Compensation yearly trend continues to be comparatively stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2018-03-31

Previous Quarter

5.4 M

Current Value

4.6 M

Quarterly Volatility

1.6 M

Covid

Check RAPT Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RAPT Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 952.3 K, Interest Expense of 1.3 M or Selling General Administrative of 14.6 M, as well as many indicators such as Price To Sales Ratio of 208, Dividend Yield of 0.0 or PTB Ratio of 6.8. RAPT financial statements analysis is a perfect complement when working with RAPT Therapeutics Valuation or Volatility modules.

Check out the analysis of RAPT Therapeutics Correlation against competitors.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

Latest RAPT Therapeutics' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of RAPT Therapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. RAPT Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in RAPT Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

RAPT Stock Based Compensation Regression Statistics

	Arithmetic Mean	4,925,837
	Geometric Mean	2,055,765
	Coefficient Of Variation	128.54
	Mean Deviation	5,374,582
	Median	716,000
	Standard Deviation	6,331,499
	Sample Variance	40.1T
	Range	17.2M
	R-Value	0.85
	Mean Square Error	12.2T
	R-Squared	0.72
	Significance	0.000069
	Slope	1,198,482
	Total Sum of Squares	561.2T

RAPT Stock Based Compensation History

	2024	17.9 M
	2023	17.1 M
	2022	11.3 M
	2021	10 M
	2020	8.7 M
	2019	2.1 M
	2018	1.2 M

Other Fundumenentals of RAPT Therapeutics

Stock Based Compensation To Revenue

RAPT Therapeutics Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Capital Stock	Current Deferred Revenue	Short Term Debt	Short Term Investments	Deferred Long Term Liab
Total Assets		0.95	0.89	0.57	-0.85	0.77	0.89	-0.72	0.95	1.0	1.0	0.91	0.26	0.87	-0.89	0.74	0.92	-0.76
Total Stockholder Equity	0.95		0.87	0.41	-0.84	0.76	0.87	-0.9	1.0	0.95	0.94	0.96	0.53	0.8	-0.81	0.75	0.81	-0.71
Net Tangible Assets	0.89	0.87		0.46	-0.97	0.83	1.0	-0.72	0.87	0.89	0.87	0.9	0.2	0.88	-0.91	0.79	0.77	-0.91
Net Debt	0.57	0.41	0.46		-0.42	0.42	0.45	-0.12	0.41	0.58	0.59	0.36	-0.33	0.49	-0.51	0.67	0.54	-0.4
Retained Earnings	-0.85	-0.84	-0.97	-0.42		-0.9	-0.99	0.7	-0.84	-0.84	-0.82	-0.91	-0.2	-0.91	0.92	-0.74	-0.73	0.95
Accounts Payable	0.77	0.76	0.83	0.42	-0.9		0.85	-0.61	0.76	0.76	0.73	0.87	0.17	0.88	-0.79	0.57	0.54	-0.8
Capital Surpluse	0.89	0.87	1.0	0.45	-0.99	0.85		-0.72	0.87	0.88	0.86	0.91	0.21	0.89	-0.93	0.78	0.78	-0.93
Total Liab	-0.72	-0.9	-0.72	-0.12	0.7	-0.61	-0.72		-0.9	-0.72	-0.7	-0.87	-0.82	-0.56	0.58	-0.64	-0.53	0.54
Net Invested Capital	0.95	1.0	0.87	0.41	-0.84	0.76	0.87	-0.9		0.95	0.94	0.96	0.53	0.8	-0.81	0.75	0.81	-0.71
Total Current Assets	1.0	0.95	0.89	0.58	-0.84	0.76	0.88	-0.72	0.95		1.0	0.9	0.26	0.86	-0.89	0.75	0.92	-0.75
Net Working Capital	1.0	0.94	0.87	0.59	-0.82	0.73	0.86	-0.7	0.94	1.0		0.88	0.25	0.85	-0.88	0.75	0.93	-0.73
Common Stock	0.91	0.96	0.9	0.36	-0.91	0.87	0.91	-0.87	0.96	0.9	0.88		0.47	0.9	-0.87	0.77	0.73	-0.81
Property Plant Equipment	0.26	0.53	0.2	-0.33	-0.2	0.17	0.21	-0.82	0.53	0.26	0.25	0.47		0.06	-0.07	0.19	0.1	-0.04
Capital Stock	0.87	0.8	0.88	0.49	-0.91	0.88	0.89	-0.56	0.8	0.86	0.85	0.9	0.06		-0.96	0.74	0.77	-0.9
Current Deferred Revenue	-0.89	-0.81	-0.91	-0.51	0.92	-0.79	-0.93	0.58	-0.81	-0.89	-0.88	-0.87	-0.07	-0.96		-0.79	-0.87	0.95
Short Term Debt	0.74	0.75	0.79	0.67	-0.74	0.57	0.78	-0.64	0.75	0.75	0.75	0.77	0.19	0.74	-0.79		0.65	-0.73
Short Term Investments	0.92	0.81	0.77	0.54	-0.73	0.54	0.78	-0.53	0.81	0.92	0.93	0.73	0.1	0.77	-0.87	0.65		-0.73
Deferred Long Term Liab	-0.76	-0.71	-0.91	-0.4	0.95	-0.8	-0.93	0.54	-0.71	-0.75	-0.73	-0.81	-0.04	-0.9	0.95	-0.73	-0.73

Click cells to compare fundamentals

About RAPT Therapeutics Financial Statements

RAPT Therapeutics shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although RAPT Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in RAPT Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on RAPT Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	17.1 M	17.9 M
Stock Based Compensation To Revenue	6.64	6.97

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

RAPT Stock Based Compensation from 2010 to 2024

Latest RAPT Therapeutics' Stock Based Compensation Growth Pattern

RAPT Stock Based Compensation Regression Statistics

RAPT Stock Based Compensation History

Other Fundumenentals of RAPT Therapeutics

RAPT Therapeutics Stock Based Compensation component correlations

About RAPT Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for RAPT Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY